Critics say a new, broader definition of high-risk plaque opens the door to more tests, diagnoses, and invasive procedures, steering us down a potentially harmful path.

These findings informed the design of the ALLAY-HFrEF trial, which is testing a novel device that creates an atrial shunt and ... clinical trial evaluating its stent graft for the treatment ...

Boston has tapped into novel platforms, including its Eluvia stent for peripheral use, subcutaneous implantable defibrillator, and left atrial appendage closure and atrial fibrillation products.

Boston has tapped into novel platforms, including its Eluvia stent for peripheral use, subcutaneous implantable defibrillator, and left atrial appendage closure and atrial fibrillation products.